单剂重组人抗血管内皮生长因子(GB222)与替莫唑胺联合治疗复发性世界卫生组织III级和IV级神经胶质瘤患者的I期试验

xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li
{"title":"单剂重组人抗血管内皮生长因子(GB222)与替莫唑胺联合治疗复发性世界卫生组织III级和IV级神经胶质瘤患者的I期试验","authors":"xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li","doi":"10.1007/s44194-022-00010-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":72735,"journal":{"name":"Current medicine (Cham, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phase I trial of single-agent recombinant human anti-vascular endothelial growth factor (GB222) followed a combination therapy of GB222 and temozolomide in patients with recurrent WHO grade III and IV glioma\",\"authors\":\"xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li\",\"doi\":\"10.1007/s44194-022-00010-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":72735,\"journal\":{\"name\":\"Current medicine (Cham, Switzerland)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current medicine (Cham, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s44194-022-00010-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicine (Cham, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44194-022-00010-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Phase I trial of single-agent recombinant human anti-vascular endothelial growth factor (GB222) followed a combination therapy of GB222 and temozolomide in patients with recurrent WHO grade III and IV glioma
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信